2021 Kasım: Güney Kore'nin bağışıklık kontrol noktası sinyallerini atlatmak için tasarlanan yerli yeni nesil kimerik antijen reseptörü T (CAR-T) hücre terapisinin ilk klinik denemesi yakın zamanda başladı.
Kore İleri Bilim ve Teknoloji Enstitüsü (KAIST) Çarşamba günü yaptığı açıklamada, CAR-T hücre tedavisinin Faz 1b klinik denemesinin şu anda Seul'deki Samsung Tıp Merkezi'nde yürütüldüğünü duyurdu. Deneme, tekrarlayan ve dirençli diffüz büyük B hücreli lenfoma hastası 10 Koreli hastayla yürütülüyor. Boru hattının pazarlama hakları üniversiteden Profesör Kim Chan-hyuk'un kurucularından olduğu Curocell şirketine devredildi. Curocell, devrim niteliğindeki klinik geliştirme programından sorumludur. immünoterapi.
In addition, a Phase 2 klinik deneme involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for kimerik antijen reseptörü T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Okumak isteyebilirsiniz: Kore'de ARABA T-Hücre tedavisi
Çalışmanın bulguları Molecular Therapy'nin Ekim sayısında çevrimiçi olarak yayınlanan bir makalede sunuldu.
